Sōvyn

09/07/2026

The HTI-1 rule expanded the information certified health IT must make available about predictive decision-support tools. Its framework includes 31 source attributes for predictive interventions, covering areas such as intended use, training data, validation and risk management.

That is a major shift in how healthcare AI will be evaluated and communicated.

A product page saying an algorithm is “clinically validated” is no longer enough. Which population? Which setting? Which outcome? Which limitations?

The strongest healthcare AI companies will treat model transparency as part of product storytelling, not a compliance appendix.

09/04/2026

In April 2026, CMS proposed requirements that would set decision deadlines for certain medical-benefit drug prior authorizations at no later than 24 hours for urgent requests and 72 hours for standard requests.

The communications opportunity is larger than “faster prior auth.”

Health tech companies need to explain how speed, clinical review, documentation quality and transparency work together. Faster decisions are valuable only if stakeholders trust the process and understand what happens when information is incomplete.

The companies shaping this category will speak to the experience of patients, providers and payers, not only the transaction. https://hubs.ly/Q04tJF-d0

09/02/2026

CMS requires impacted payers to implement key interoperability APIs by January 1, 2027, including provider access, payer-to-payer, and prior authorization capabilities.

For health tech companies, this is more than a compliance deadline. It’s an opportunity to lead through education.
The vendors that stand out will simplify what’s changing: what payers need to do, what providers need to know, what data must move, and how organizations can prepare.

In regulation-driven markets, the companies that educate and build confidence create the most value.

08/31/2026

Under the CMS Interoperability and Prior Authorization Final Rule, impacted payers had to publish their first set of prior authorization metrics by March 31, 2026, covering calendar year 2025.

That creates a new communications reality. Approval rates, denial rates and decision times are no longer merely internal operational measures. They are public evidence that providers, customers, journalists and competitors can examine.

Payers should be prepared to explain the numbers, the context behind them and the actions being taken to improve.

Health tech vendors should be equally prepared to show how their products affect measurable performance, not simply promise “streamlined workflows.”

At Sōvyn, we see public performance data as more than a reporting requirement. It is the raw material for a credible market narrative.

08/28/2026

The International Energy Agency projects global data-center electricity consumption will more than double to roughly 945 terawatt-hours by 2030. AI is the largest driver of that growth.

The sustainability conversation around AI can no longer be reduced to a paragraph in an ESG report.

Customers, employees, policymakers and communities will increasingly ask where computing capacity comes from, how efficiently it is used and what tradeoffs accompany scale.

Companies that communicate only the benefits of AI leave an obvious credibility gap. Mature thought leadership addresses both value and cost, then explains what the organization is doing about the tension.

https://hubs.ly/Q04sgvNQ0

08/24/2026

Colorado’s consumer protections for high-risk AI systems took effect June 30, 2026, after lawmakers extended the original implementation date.

The law focuses on consequential decisions, including decisions that can materially affect access to areas such as employment, housing, healthcare and financial services.

For vendors, this raises an important marketing question: can your company explain not only what its model predicts, but how that prediction is used?

Buyers increasingly want documentation, risk controls and clear accountability. Those materials should not live exclusively in procurement folders. They should inform sales enablement, website language and executive thought leadership.

Transparency is moving from policy language into the buying journey.

08/20/2026

The EU Data Act has applied since September 12, 2025. Among other goals, it gives users greater control over data generated by connected products and creates new opportunities for data sharing and aftermarket services.

For IoT companies, the value proposition can no longer stop at the device.

The better story is what authorized access to device data makes possible: better service, more competition, faster maintenance, new partnerships and clearer customer control.

But companies also need to explain the boundaries. Who can access what? Under which conditions? How is confidential information protected?

In the connected economy, data access is a product feature, a legal obligation and a communications challenge at the same time.

08/17/2026

The Texas Responsible Artificial Intelligence Governance Act took effect January 1, 2026. It includes restrictions on certain harmful uses of AI and establishes an AI regulatory sandbox.

The broader lesson is that U.S. AI regulation is developing state by state.

That creates a messaging risk for vendors selling nationally. A claim that is technically accurate in one market may be incomplete in another. A generic “responsible AI” page is not enough if the sales team cannot answer concrete questions about deployment, monitoring and prohibited uses.

Companies need a living message architecture that connects product claims to the jurisdictions and use cases in which the technology actually operates. https://hubs.ly/Q04rtGTG0

08/14/2026

A new chapter in kidney transplant is taking shape in Edmonton. 🩺🫀

The University of Alberta Hospital is the first to implement XVIVO’s Kidney Assist Transport technology, helping improve how donor kidneys are preserved and transported to patients.

A promising step forward for organ preservation and transplant care. 💙

🔗 https://hubs.ly/Q04t3Z9h0

Edmonton is the first centre in Canada to utilize the XVIVO Kidney Assist Transport, which has proven to help in patient recovery after the kidney has been transplanted.

08/14/2026

The EU AI Act entered into force in 2024, but its requirements arrive in stages. Prohibited practices and AI literacy obligations began applying in February 2025. General-purpose AI obligations followed in August 2025. Other high-risk requirements have later dates.

For technology companies, “We are AI Act compliant” is often too broad to be meaningful.

A stronger message explains which requirements apply, what the company has already done and how governance will evolve. Buyers do not need a recital of the regulation. They need evidence that the vendor understands its own risk profile.

Regulatory fluency is becoming part of brand credibility. https://hubs.ly/Q04rtzfT0